Diverse mechanisms of PARP inhibitor resistance in ovarian cancer

被引：18
|
作者：
Wakefield, Matthew John [1 ,2 ]
Nesic, Ksenija [1 ,3 ]
Kondrashova, Olga [4 ]
Scott, Clare L. [1 ,2 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Royal Womens Hosp, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia
[4] QIMR Berghofer Med Res Inst, Herston, Qld 4006, Australia
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2019年 / 1872卷 / 02期
基金：
英国医学研究理事会;
关键词：
REPLICATION FORK REVERSAL; CELL-FREE DNA; HOMOLOGOUS RECOMBINATION; MRE11-DEPENDENT DEGRADATION; GERMLINE MUTATIONS; EXCISION-REPAIR; MUTANT-CELLS; NASCENT DNA; BRCA2; STABILITY;
D O I：
10.1016/j.bbcan.2019.08.002
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 50 条
  • [31] HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
    Ma, Hanlin
    Qi, Gonghua
    Han, Fang
    Lu, Wei
    Peng, Jiali
    Li, Rongrong
    Yan, Shi
    Yuan, Cunzhong
    Kong, Beihua
    [J]. CELL DEATH & DISEASE, 2022, 13 (03)
  • [32] HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
    Hanlin Ma
    Gonghua Qi
    Fang Han
    Wei Lu
    Jiali Peng
    Rongrong Li
    Shi Yan
    Cunzhong Yuan
    Beihua Kong
    [J]. Cell Death & Disease, 13
  • [33] In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
    Z. Ping Lin
    Nour N. Al Zouabi
    Mark L. Xu
    Nicole E. Bowen
    Terence L. Wu
    Ethan S. Lavi
    Pamela H. Huang
    Yong-Lian Zhu
    Baek Kim
    Elena S. Ratner
    [J]. Scientific Reports, 11
  • [34] In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
    Lin, Z. Ping
    Al Zouabi, Nour N.
    Xu, Mark L.
    Bowen, Nicole E.
    Wu, Terence L.
    Lavi, Ethan S.
    Huang, Pamela H.
    Zhu, Yong-Lian
    Kim, Baek
    Ratner, Elena S.
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [35] Different treatment schemes cause distinct PARP inhibitor resistance mechanisms in BRCA2-mutant ovarian cancer cells
    Huang, Tzu-Ting
    Nair, Jayakumar R.
    Gupta, Nitasha
    Yamamoto, Tomomi M.
    Bitler, Benjamin G.
    Lee, Jung-Min
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [36] KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
    Wu, Yong
    Chen, Siyu
    Shao, Yang
    Su, Ying
    Li, Qin
    Wu, Jiangchun
    Zhu, Jun
    Wen, Hao
    Huang, Yan
    Zheng, Zhong
    Chen, Xiaojun
    Ju, Xingzhu
    Huang, Shenglin
    Wu, Xiaohua
    Hu, Zhixiang
    [J]. ADVANCED SCIENCE, 2023, 10 (31)
  • [37] ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer
    McMellen, Alexandra
    Yamamoto, Tomomi M.
    Qamar, Lubna
    Sanders, Brooke E.
    Nguyen, Lily L.
    Chavez, Daniela Ortiz
    Bapat, Jaidev
    Berning, Amber
    Post, Miriam D.
    Johnson, Joshua
    Behbakht, Kian
    Nurmemmedov, Elmar
    Chuong, Edward B.
    Bitler, Benjamin G.
    [J]. MOLECULAR CANCER RESEARCH, 2023, 21 (01) : 3 - 13
  • [38] Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer
    Jenks, Andrew D.
    Vyse, Simon
    Wong, Jocelyn P.
    Kostaras, Eleftherios
    Keller, Deborah
    Burgoyne, Thomas
    Shoemark, Amelia
    Tsalikis, Athanasios
    de la Roche, Maike
    Michaelis, Martin
    Cinatl, Jindrich, Jr.
    Huang, Paul H.
    Tanos, Barbara E.
    [J]. CELL REPORTS, 2018, 23 (10): : 3042 - 3055
  • [39] PARP inhibitor resistance: the underlying mechanisms and clinical implications
    He Li
    Zhao-Yi Liu
    Nayiyuan Wu
    Yong-Chang Chen
    Quan Cheng
    Jing Wang
    [J]. Molecular Cancer, 19
  • [40] PARP inhibitor resistance: the underlying mechanisms and clinical implications
    Li, He
    Liu, Zhao-Yi
    Wu, Nayiyuan
    Chen, Yong-Chang
    Cheng, Quan
    Wang, Jing
    [J]. MOLECULAR CANCER, 2020, 19 (01)
12345